We are committed to the research and discovery of novel pathways and therapies to address some of the world's most serious psychiatric conditions. Our goal is to develop therapies that transform the lives of people living with these conditions.
LATUDA® (lurasidone HCl) is indicated:
- for the management of the manifestations of schizophrenia.
- as monotherapy or as adjunctive therapy with lithium or valproate for the acute management of depressive episodes associated with bipolar I disorder.